Barclays Upgrades uniQure BV (QURE) to Overweight Following 78% Gain Yesterday Jun 18, 2026 08:11AM
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE) Jun 18, 2026 06:48AM
uniQure BV (QURE) PT Raised to $70 at Leerink Jun 18, 2026 06:44AM
Goldman Sachs on uniQure BV (QURE): 'we now expect a US approval in 2Q27 (vs. 2030 prior, assuming priority review...' Jun 17, 2026 01:29PM
Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent' Jun 17, 2026 01:27PM
View Older Stories

Jun 17, 2026 11:49AM Cantor Fitzgerald Upgrades uniQure BV (QURE) to Overweight
Jun 17, 2026 09:31AM uniQure BV (QURE) PT Raised to $71 at Stifel
Jun 17, 2026 09:11AM Barclays Comments on uniQure BV (QURE) Amid 66% Gain: 'a major positive'
Jun 17, 2026 07:22AM uniQure (QURE) to resume trading at 7:35 a.m.
Jun 17, 2026 07:21AM ClearPoint Neuro stock surges on peer's FDA approval plan
Jun 17, 2026 07:06AM uniQure plans BLA submission for Huntington's therapy in Q3 2026
May 12, 2026 12:50PM FDA Commissioner Marty Makary is resigning - Politico reporter on X
May 5, 2026 07:28AM uniQure (QURE) Tops Q1 EPS by 2c
Apr 30, 2026 07:06AM uniQure plans UK regulatory filing for Huntington's disease gene therapy
Mar 10, 2026 04:21PM Mizuho Upgrades uniQure BV (QURE) to Outperform, Raise PT to $35
Mar 9, 2026 01:04PM uniQure BV (QURE) PT Raised to $31 at Chardan
Mar 9, 2026 07:46AM Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'
Mar 9, 2026 07:39AM Mizuho's Jared Holz: 'We still like the sector, despite some recent setbacks like QURE and others'
Mar 9, 2026 07:38AM Stifel: 'Prasad is Out, QURE is on the Map, and Rare Disease Has Political Tailwinds'
Mar 9, 2026 07:11AM Wells Fargo Upgrades uniQure BV (QURE) to Overweight
Mar 9, 2026 05:34AM RBC Capital Upgrades uniQure BV (QURE) to Outperform
Mar 3, 2026 06:31AM TD Cowen Reiterates Buy Rating on uniQure BV (QURE)
Mar 3, 2026 04:44AM Wells Fargo Downgrades uniQure BV (QURE) to Equal Weight
Mar 3, 2026 02:16AM Mizuho Downgrades uniQure BV (QURE) to Neutral
Mar 2, 2026 04:07PM uniQure BV (QURE) PT Lowered to $35 at Leerink Partners
Mar 2, 2026 11:33AM RBC Capital Downgrades uniQure BV (QURE) to Sector Perform, Lowers PT to $11
Mar 2, 2026 11:23AM uniQure BV (QURE) PT Lowered to $14 at Stifel on FDA uncertainty
Mar 2, 2026 11:02AM Cantor Fitzgerald Downgrades uniQure BV (QURE) to Neutral following FDA recommendation
Mar 2, 2026 07:57AM Stifel Reiterates Buy Rating on uniQure BV (QURE)
Mar 2, 2026 07:02AM uniQure faces FDA hurdle for Huntington's disease gene therapy
Feb 26, 2026 02:28PM RBC Capita on uniQure BV (QURE): 'The Commissioner's comments are clearly disappointing'
Feb 26, 2026 11:53AM Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
Feb 26, 2026 09:48AM UniQure stock tumbles on FDA comments about gene therapy trial
Feb 24, 2026 09:12AM Wolfe Research Starts uniQure BV (QURE) at Peerperform
Feb 6, 2026 11:10AM Options with increasing option implied volatility: MSTU XXRP ETHU QURE MSTZ BITX
Feb 6, 2026 07:06AM uniQure reports sustained enzyme activity in Fabry disease gene therapy trial
Feb 2, 2026 03:12PM uniQure (QURE) call put ratio 5.8 calls to 1 put with a focus on March 15 puts and April 70 calls
Jan 23, 2026 06:48AM H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
Jan 14, 2026 07:04AM uniQure (QURE) Reiterated at Overweight by Cantor Fitzgerald: FDA Feedback Key
Jan 12, 2026 05:11AM uniQure (QURE) spreader of 6K contracts of April 30 and 40 calls
Jan 9, 2026 07:05AM uniQure schedules FDA meeting on Huntington's therapy approval
Dec 9, 2025 04:29AM uniQure BV (QURE) PT Lowered to $33 at Mizuho
Dec 4, 2025 07:06AM uniQure receives FDA feedback on Huntington's disease gene therapy
Nov 11, 2025 04:32AM William Blair Reiterates Market Perform Rating on uniQure BV (QURE)
Nov 10, 2025 02:54PM uniQure BV (QURE) PT Lowered to $50 at Stifel
Nov 10, 2025 01:18PM uniQure BV (QURE) PT Lowered to $60 at Leerink Partners
Nov 10, 2025 07:09AM uniQure (QURE) Misses Q3 EPS by 47c
Nov 5, 2025 08:16AM Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'
Nov 4, 2025 08:44AM uniQure BV (QURE) PT Lowered at RBC Capital After a 'Disappointing Regulatory Update'
Nov 4, 2025 06:43AM uniQure BV (QURE) PT Lowered to $70 at H.C. Wainwright, maintained as Top Pick
Nov 4, 2025 04:17AM William Blair Downgrades uniQure BV (QURE) to Market Perform
Nov 3, 2025 10:00AM Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
Nov 3, 2025 09:38AM uniQure (QURE) halted on volatility
Nov 3, 2025 09:24AM Raymond James on Biohaven (BHVN) Amid News Shock: 'QURE Sympathy Move Seems Misplaced'
Nov 3, 2025 07:38AM Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease
View Older Stories